Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1Advanced Cancer 1

Interventions

Cyclophosphamide 110fludarabine phosphate 106Busulfan 84Azacitidine 73Peripheral Blood Stem Cell Transplantation 64Mycophenolic Acid 64Antilymphocyte Serum 64Cytarabine 63Tacrolimus 62fludarabine 61Cyclosporine 56Filgrastim 55Whole-Body Irradiation 52Methotrexate 47Melphalan 42Decitabine 42Radiotherapy 37Clofarabine 29Granulocyte Colony-Stimulating Factor 28Cord Blood Stem Cell Transplantation 28Methylprednisolone 24Etoposide 24thymoglobulin 21Thiotepa 21Stem Cell Transplantation 21sargramostim 19Sirolimus 16Alemtuzumab 15Lenalidomide 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Myelodysplastic Syndromes × IDO-1 inhibitor LY3381916 × Clear all
NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡